Recommended as first-line treatment per the
RRP Foundation position statement.1,2

PAPZIMEOS resource library

Resources for your practice

About PAPZIMEOS

Dive deeper into PAPZIMEOS efficacy, safety, dosing, and more.

Efficacy & Safety

Dive into clinical studies and data to better understand how PAPZIMEOS may help your patients.

PAPZIMEOS Brochure

Dosing & Administration

Learn how to properly prepare and inject PAPZIMEOS.

Dosing & Administration Guide

Papzimeos SUPPORT

Start here to help your patients learn about the Papzimeos SUPPORT program

Papzimeos SUPPORT

Explore how Precigen can support your patients and care team. For questions or to get started, call (866) 827-8180.

Papzimeos SUPPORT Brochure

Papzimeos SUPPORT Enrollment Form

Enroll your patients in Papzimeos SUPPORT for support throughout the access process.

Enroll in Papzimeos SUPPORT online

Papzimeos SUPPORT Enrollment Form

Papzimeos SUPPORT Copay Assistance Program

Learn about the copay assistance program for eligible patients.

Papzimeos SUPPORT Copay Assistance

Getting PAPZIMEOS

Take the next step. Find out about product ordering, the billing and coding process, reimbursement, and more.

How to Order

Follow this step-by-step process for ordering and receiving PAPZIMEOS shipments.

Distribution & Product Ordering Guide

Billing & Coding

Submit claims with billing and coding resources for PAPZIMEOS.

Billing & Coding Guide

Best Practices for PA Process

Learn how to navigate the prior authorization process for PAPZIMEOS.

Best Practices for PA Process Guide

Sample Letters for Coverage

These templates can be used to help support an insurer’s coverage of PAPZIMEOS.

Sample Letter of Medical Necessity
Sample Letter of Appeal

Navigating Access & Getting Started

Follow this guide to navigate the access and reimbursement process for PAPZIMEOS.

Navigating Access & Getting Started Guide

PA=prior authorization

For your patients

Resources to help your patients as they get started with PAPZIMEOS.

PAPZIMEOS for Patients

Help your patients learn more about PAPZIMEOS.

Patient Brochure

Site Locator

See where patients can find the nearest treatment centers.

Site Locator Tool

Dosing Scheduler

Patients can refer to this guide to track PAPZIMEOS treatment.

Dosing Guide

Sign up & connect

Learn more about PAPZIMEOS or connect with a PAPZIMEOS representative.

Register today

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Indication and Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

Please see full Prescribing Information.

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Indication and
Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

Please see full Prescribing Information.

INDICATION

PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.

Important Safety Information

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.

Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.

ADVERSE REACTIONS

The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data with PAPZIMEOS in pregnant women.

Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.

Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.

Please see full Prescribing Information.

  1. References:
  2. PAPZIMEOS. Package insert. Precigen, Inc; 2025.
  3. Best SR, Friedman AD, Rosen CA, et al. Recurrent Respiratory Papillomatosis Foundation position statement on the management of adults with RRP. Laryngoscope. 2026;136(suppl 4):S7–S17. doi:10.1002/lary.70379